Related references
Note: Only part of the references are listed.Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
Mary Pritzlaff et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls
Jenna Lilyquist et al.
GYNECOLOGIC ONCOLOGY (2017)
Multigene Panel Testing Provides a New Perspective on Lynch Syndrome
Carin R. Espenschied et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Fergus J. Couch et al.
JAMA ONCOLOGY (2017)
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
Sanna Hallamies et al.
BMC CANCER (2017)
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing
Lisa R. Susswein et al.
GENETICS IN MEDICINE (2016)
Frameshift variant FANCL*c.1096_1099dupATTA is not associated with high breast cancer risk
K. Pfeifer et al.
CLINICAL GENETICS (2016)
RE: frameshift variant FANCL*c.1096_1099dupATTA is not associated with high breast cancer risk
P. Zemankova et al.
CLINICAL GENETICS (2016)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
Valentina Silvestri et al.
BREAST CANCER RESEARCH (2016)
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer
Nimmi S. Kapoor et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Lynch Syndrome Caused by Germline PMS2 Mutations: Delineating the Cancer Risk
Sanne W. ten Broeke et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases
Paraskevi Apostolou et al.
CANCER GENETICS (2015)
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment
Andrea Desmond et al.
JAMA ONCOLOGY (2015)
Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel
Nadine Tung et al.
CANCER (2015)
High prevalence of BRCA1 founder mutations in Greek breast/ovarian families
I. Konstantopoulou et al.
CLINICAL GENETICS (2014)
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Neurofibromatosis type I with breast cancer: not only for women!
Kuntegowdanahalli Chinnagiriyappa Lakshmaiah et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2014)
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy
Laura Ottini et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
Florentia Fostira et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Nicholas J. Roberts et al.
CANCER DISCOVERY (2012)
Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States
Yuan Chun Ding et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome
Valerie Bonadona et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Larissa A. Korde et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CHEK2 1100delC and male breast cancer in the Netherlands
Marijke Wasielewski et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations
Leigha Senter et al.
GASTROENTEROLOGY (2008)
ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007
C. Sue Richards et al.
GENETICS IN MEDICINE (2008)
Prospective Evaluation of Risk Factors for Male Breast Cancer
Louise A. Brinton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers
Yu Chuan Tai et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
Anthony Renwick et al.
NATURE GENETICS (2006)
BRCA2 mutations in 154 Finnish male breast cancer patients
K Syrjakoski et al.
NEOPLASIA (2004)
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer
P Vahteristo et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations
H Meijers-Heijboer et al.
NATURE GENETICS (2002)
Male breast cancer in Cowden syndrome patients with germline PTEN mutations
JD Fackenthal et al.
JOURNAL OF MEDICAL GENETICS (2001)
Share Paper
